Ablation of Osteopontin Improves the Skeletal Phenotype of Phospho1−/− Mice

PHOSPHO1 and tissue‐nonspecific alkaline phosphatase (TNAP) have nonredundant functions during skeletal mineralization. Although TNAP deficiency (Alpl−/− mice) leads to hypophosphatasia, caused by accumulation of the mineralization inhibitor inorganic pyrophosphate (PPi), comparably elevated levels of PPi in Phospho1−/− mice do not explain their stunted growth, spontaneous fractures, bowed long bones, osteomalacia, and scoliosis. We have previously shown that elevated PPi in Alpl−/− mice is accompanied by elevated osteopontin (OPN), another potent mineralization inhibitor, and that the amount of OPN correlates with the severity of hypophosphatasia in mice. Here we demonstrate that plasma OPN is elevated and OPN expression is upregulated in the skeleton, particularly in the vertebrae, of Phospho1−/− mice. Liquid chromatography/tandem mass spectrometry showed an increased proportion of phosphorylated OPN (p‐OPN) peptides in Phospho1−/− mice, suggesting that accumulation of p‐OPN causes the skeletal abnormalities in Phospho1−/− mice. We also show that ablation of the OPN gene, Spp1, leads to improvements in the skeletal phenotype in Phospho1−/− as they age. In particular, their scoliosis is ameliorated at 1 month of age and is completely rescued at 3 months of age. There is also improvement in the long bone defects characteristic of Phospho1−/− mice at 3 months of age. Mineralization assays comparing [Phospho1−/−; Spp1−/−], Phospho1−/−, and Spp1−/− chondrocytes display corrected mineralization by the double knockout cells. Expression of chondrocyte differentiation markers was also normalized in the [Phospho1−/−; Spp1−/−] mice. Thus, although Alpl and Phospho1 deficiencies lead to similar skeletal phenotypes and comparable changes in the expression levels of PPi and OPN, there is a clear dissociation in the hierarchical roles of these potent inhibitors of mineralization, with elevated PPi and elevated p‐OPN levels causing the respective skeletal phenotypes in Alpl−/− and Phospho1−/− mice. © 2014 American Society for Bone and Mineral Research.

[1]  J. Millán,et al.  In Vivo Overexpression of Tissue‐Nonspecific Alkaline Phosphatase Increases Skeletal Mineralization and Affects the Phosphorylation Status of Osteopontin , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. McKee,et al.  Compounded PHOSPHO1/ALPL Deficiencies Reduce Dentin Mineralization , 2013, Journal of dental research.

[3]  G. Hunter Role of Osteopontin in Modulation of Hydroxyapatite Formation , 2013, Calcified Tissue International.

[4]  J. Millán The Role of Phosphatases in the Initiation of Skeletal Mineralization , 2012, Calcified Tissue International.

[5]  Nick Bishop,et al.  Enzyme-replacement therapy in life-threatening hypophosphatasia. , 2012, The New England journal of medicine.

[6]  M. McKee,et al.  Loss of Skeletal Mineralization by the Simultaneous Ablation of PHOSPHO1 and Alkaline Phosphatase Function: A Unified Model of the Mechanisms of Initiation of Skeletal Calcification , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  Simon R. Goodyear,et al.  PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. , 2010, Bone.

[8]  Jeffrey J. Gray,et al.  Phosphorylation‐dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  R. Terkeltaub,et al.  Inorganic pyrophosphatase induces type I collagen in osteoblasts. , 2010, Bone.

[10]  R. Terkeltaub,et al.  Enzyme Replacement Therapy for Murine Hypophosphatasia , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  A. Evan,et al.  Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. , 2007, American journal of physiology. Renal physiology.

[12]  M. McKee,et al.  Pyrophosphate Inhibits Mineralization of Osteoblast Cultures by Binding to Mineral, Up-regulating Osteopontin, and Inhibiting Alkaline Phosphatase Activity* , 2007, Journal of Biological Chemistry.

[13]  J. Millán,et al.  Functional Involvement of PHOSPHO1 in Matrix Vesicle–Mediated Skeletal Mineralization , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  C. Farquharson,et al.  The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior to skeletal mineralization. , 2006, Bone.

[15]  R. Terkeltaub,et al.  Elevated Skeletal Osteopontin Levels Contribute to the Hypophosphatasia Phenotype in Akp2−/− Mice , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  M. McKee,et al.  Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. , 2005, Genes & development.

[17]  R. Terkeltaub,et al.  Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. , 2004, The American journal of pathology.

[18]  R. Terkeltaub,et al.  Linked Deficiencies in Extracellular PPi and Osteopontin Mediate Pathologic Calcification Associated With Defective PC‐1 and ANK Expression , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  A. Boskey,et al.  Osteopontin Facilitates Bone Resorption, Decreasing Bone Mineral Crystallinity and Content During Calcium Deficiency , 2003, Calcified Tissue International.

[20]  C. Alpers,et al.  J Am Soc Nephrol 14: 139–147, 2003 Osteopontin Is a Critical Inhibitor of Calcium Oxalate Crystal Formation and Retention in Renal Tubules , 2022 .

[21]  M. McKee,et al.  Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. , 2002, The American journal of pathology.

[22]  R. Guldberg,et al.  Inactivation of the Osteopontin Gene Enhances Vascular Calcification of Matrix Gla Protein–deficient Mice , 2002, The Journal of experimental medicine.

[23]  R. Terkeltaub,et al.  Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Boskey,et al.  Osteopontin Deficiency Increases Mineral Content and Mineral Crystallinity in Mouse Bone , 2002, Calcified Tissue International.

[25]  S. Narisawa,et al.  Abnormal vitamin B6 metabolism in alkaline phosphatase knock‐out mice causes multiple abnormalities, but not the impaired bone mineralization , 2001, The Journal of pathology.

[26]  D. Denhardt,et al.  Osteopontin Function in Pathology: Lessons from Osteopontin-Deficient Mice , 1999, Nephron Experimental Nephrology.

[27]  M. McKee,et al.  Mice Lacking Osteopontin Show Normal Development and Bone Structure but Display Altered Osteoclast Formation In Vitro , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  T. Ushida,et al.  Osteopontin involvement in integrin‐mediated cell signaling and regulation of expression of alkaline phosphatase during early differentiation of UMR cells , 1997, FEBS letters.

[29]  P. Højrup,et al.  Posttranslational modifications of bovine osteopontin: Identification of twenty‐eight phosphorylation and three O‐glycosylation sites , 1995, Protein science : a publication of the Protein Society.

[30]  G. Hunter,et al.  Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. , 1994, The Biochemical journal.

[31]  A. Boskey,et al.  Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. , 1993, Bone and mineral.

[32]  R. Schrohenloher,et al.  Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. , 1987, The Journal of biological chemistry.

[33]  D. Heinegård,et al.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Mcalister,et al.  Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: results in three additional patients. , 1984, The Journal of pediatrics.

[35]  W. Mcalister,et al.  Infantile hypophosphatasia: enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. , 1982, The Journal of pediatrics.